Whitepaper challenges WHO stance on e-cigarettes.

Jan.05.2023
Whitepaper challenges WHO stance on e-cigarettes.
A white paper criticizes the WHO's opposition to the e-cigarette movement. THR experts refute the gateway theory to smoking.

A whitepaper has criticized the World Health Organization's (WHO) opposition to the e-cigarette movement. Nancy Loucas, the Executive Coordinator of the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), stated that the document greatly helps to expose the WHO's misleading rhetoric aimed at smokers and decision-makers.


Nancy Loucas stated that "this white paper completely discredits and refutes the prevalent notion among young people that e-cigarettes are a gateway to smoking.


After compiling and publishing the book "Disrupting Public Health: A Consumer Perspective," several leading international experts in tobacco harm reduction (THR) criticized the World Health Organization's stance, which attracted considerable attention from readers and the media. Her commentary was among those critiques.


Over the past decade, there has been a significant increase in e-cigarette use among high schoolers and young people. However, fortunately, there has been a significant decrease in e-cigarette use since reaching its peak in 2019. During the same period, smoking rates have continued to decline to record lows. The authors of a new report suggest that these trends contradict using e-cigarettes as a gateway to smoking.


The document points out that e-cigarettes among adolescents and young adults are a legitimate concern. However, it provides a comprehensive reference for doctors, researchers, and government funding agencies, all of whom refute any claims about the gateway theory.


The white paper provides a wealth of the latest information on e-cigarette patterns among American youth and young adults. There is no doubt that e-cigarettes are a gateway to smoking, not a slope," said Ms. Loucas.


According to the Centers for Disease Control and Prevention (CDC), the youth e-cigarette rate in the United States has been steadily declining since 2020. CDC data shows that over the past two years, youth e-cigarette use has plummeted by 60%. The white paper states that only 3.1% of high school-aged students and 0.3% of middle school-aged students use e-cigarettes on a daily basis.


We are simply demanding regulations based on evidence and objective policy discussions, decisions, and risk assessment. In November 2023, the world will witness the tenth session of the Conference of the Parties, where attention will be focused on the World Health Organization and many international representatives, whether they will finally start accepting evidence instead of perpetuating the stigma against safer nicotine products," said Ms. Loucas.


Recently, nine member organizations of CAPHRA wrote letters to FCTC delegates from around the world, as well as health ministers and leaders, urging them to review evidence supporting THR methods before COP10.


The tenth meeting of the Conference of the Parties (COP10) will be held in Panama and hosted by the World Health Organization's Framework Convention on Tobacco Control (FCTC).


We will continue to disseminate and challenge key aspects of the World Health Organization's recommendations to the signatories and representatives of the FCTC, regarding the most effective tools for smoking cessation," said Nancy Loucas.


Ms. Loucas presented "Subverting Public Health: A Consumer's Perspective" at the recent 5th Asia Harm Reduction Forum (AHRF 2022).



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
The Zhengzhou Tobacco Research Institute of China National Tobacco Corporation has filed a patent application for an end-to-end method to analyze the migration and transformation of chemical compounds in heated tobacco products. Using GC-Orbitrap/MS non-targeted analysis, the method compares tobacco substrate and aerosol samples to distinguish compounds transferred directly from the substrate from those newly formed during heating, while also calculating transfer rates. In an example involving nine heated tobacco products, the patent identified 17 newly formed thermal decomposition compounds and 38 transferred compounds.
Aug.13
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
Trump Names Darrell Scott as CDC Tobacco Health Adviser, Citing Tobacco Risks and Harm-Reduction Solutions
U.S. President Donald Trump has named Pastor Darrell Scott to serve as an adviser on tobacco health issues on the Centers for Disease Control and Prevention’s Advisory Committee to the Director. Trump said Scott would focus on the burden of tobacco-related disease and help examine ways to protect Americans from dangerous tobacco products while supporting solutions that reduce harm. Scott’s public career has largely centered on faith leadership, community advocacy and politics.
Sep.02
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
U.S. Appeals Court Says BAT Must Face Class Action Over Cigarette Labels
U.S. Appeals Court Says BAT Must Face Class Action Over Cigarette Labels
A U.S. appeals court ruled that British American Tobacco (BAT) must continue facing a consumer class action lawsuit over cigarette labels. The ruling allows the case to proceed but does not determine that BAT violated the law or is liable for damages. The case highlights ongoing legal risks facing major tobacco companies related to product labeling, consumer disclosures and product liability claims.
Jul.31
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08